Ovid Therapeutics

OVIDNASDAQ
$0.769200
0.045.89%
At Close: -
$0.732000
-0.04-4.84%
After Hours: 6:08 PM EDT
15 minutes delayed
Ovid Therapeutics (OVID) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$8.00
Lowest Price Target1
$1.20
Consensus Price Target1
$4.74

Ovid Therapeutics (NASDAQ:OVID) Stock, Analyst Ratings, Price Targets, Predictions

Ovid Therapeutics Inc has a consensus price target of $4.74, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from BTIG, B. Riley Securities, and Citigroup on June 18, 2024. With an average price target of $3.07 between BTIG, B. Riley Securities, and Citigroup, there's an implied 318.94% upside for Ovid Therapeutics Inc from these 3 analyst ratings.

Analyst Trends and Forecast
1
Apr
1
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

BTIG
B. Riley Securities
Citigroup
HC Wainwright & Co.
Wedbush

1calculated from analyst ratings

Analyst Ratings for Ovid Therapeutics

Buy NowGet Alert
06/18/2024Buy Now583.06%BTIG
Thomas Shrader
$11 → $5MaintainsBuyGet Alert
06/18/2024Buy Now309.84%B. Riley Securities
Kalpit Patel
$9 → $3MaintainsBuyGet Alert
06/18/2024Buy Now63.93%Citigroup
Yigal Nochomovitz
$3.5 → $1.2MaintainsNeutralGet Alert
06/18/2024Buy Now309.84%HC Wainwright & Co.
Raghuram Selvaraju
$9 → $3MaintainsBuyGet Alert
05/16/2024Buy Now1129.51%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
05/07/2024Buy Now378.14%Citigroup
Yigal Nochomovitz
$4 → $3.5MaintainsNeutralGet Alert
04/30/2024Buy Now1129.51%B. Riley Securities
Kalpit Patel
 → $9Initiates → BuyGet Alert
04/29/2024Buy Now1129.51%HC Wainwright & Co.
Raghuram Selvaraju
 → $9Initiates → BuyGet Alert
04/05/2024Buy Now992.9%Wedbush
Laura Chico
 → $8Initiates → OutperformGet Alert
12/21/2023Buy Now1402.73%BTIG
Thomas Shrader
 → $11Initiates → BuyGet Alert
06/14/2023Buy Now719.67%JonesTrading
Sean Kim
 → $6Initiates → BuyGet Alert
05/02/2023Buy Now856.28%Ladenburg Thalmann
Michael Higgins
 → $7Reiterates → BuyGet Alert
08/29/2022Buy Now241.53%Citigroup
Yigal Nochomovitz
$2.4 → $2.5MaintainsNeutralGet Alert
05/20/2022Buy Now227.87%Citigroup
Yigal Nochomovitz
$4 → $2.4MaintainsNeutralGet Alert
08/25/2021Buy Now446.45%Citigroup
Yigal Nochomovitz
—MaintainsNeutralGet Alert

FAQ

Q

What is the target price for Ovid Therapeutics (OVID) stock?

A

The latest price target for Ovid Therapeutics (NASDAQ:OVID) was reported by BTIG on June 18, 2024. The analyst firm set a price target for $5.00 expecting OVID to rise to within 12 months (a possible 583.06% upside). 10 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Ovid Therapeutics (OVID)?

A

The latest analyst rating for Ovid Therapeutics (NASDAQ:OVID) was provided by BTIG, and Ovid Therapeutics maintained their buy rating.

Q

When was the last upgrade for Ovid Therapeutics (OVID)?

A

There is no last upgrade for Ovid Therapeutics

Q

When was the last downgrade for Ovid Therapeutics (OVID)?

A

There is no last downgrade for Ovid Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Ovid Therapeutics (OVID)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ovid Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ovid Therapeutics was filed on June 18, 2024 so you should expect the next rating to be made available sometime around June 18, 2025.

Q

Is the Analyst Rating Ovid Therapeutics (OVID) correct?

A

While ratings are subjective and will change, the latest Ovid Therapeutics (OVID) rating was a maintained with a price target of $11.00 to $5.00. The current price Ovid Therapeutics (OVID) is trading at is $0.73, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch